eprintid: 10183313 rev_number: 7 eprint_status: archive userid: 699 dir: disk0/10/18/33/13 datestamp: 2023-12-07 17:36:10 lastmod: 2023-12-07 17:36:10 status_changed: 2023-12-07 17:36:10 type: article metadata_visibility: show sword_depositor: 699 creators_name: Tremblay, Samuel creators_name: Alhogbani, Mofarej creators_name: Weickhardt, Andrew creators_name: Davis, Ian D creators_name: Scott, Andrew M creators_name: Hicks, Rodney J creators_name: Metser, Ur creators_name: Chua, Sue creators_name: Davda, Reena creators_name: Punwani, Shonit creators_name: Payne, Heather creators_name: Tunariu, Nina creators_name: Ho, Bao creators_name: Young, Sympascho creators_name: Singbo, Mahukpe Narcisse Ulrich creators_name: Bauman, Glenn creators_name: Emmett, Louise creators_name: Pouliot, Frederic title: Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial ispublished: pub divisions: UCL divisions: B02 divisions: C10 divisions: D17 divisions: FI6 keywords: Prostate cancer, Biochemical recurrence, Molecular imaging, PSMA, Choline note: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. abstract: Background: The impact of molecular imaging (MI) on patient management after biochemical recurrence (BCR) following radical prostatectomy has been described in many studies. However, it is not known if MI-induced management changes are appropriate. This study aimed to determine if androgen deprivation therapy (ADT) management plan is improved by MI in patients who are candidates for salvage radiation therapy. / Methods: Data were analyzed from the multicenter prospective PROPS trial evaluating PSMA/Choline PET in patients being considered for salvage radiotherapy (sRT) with BCR after prostatectomy. We compared the pre- and post-MI ADT management plans for each patient and cancer outcomes as predicted by the MSKCC nomogram. A higher percentage of predicted BCR associated with ADT treatment intensification after MI was considered as an improvement in a patient’s management. / Results: Seventy-three patients with a median PSA of 0.38 ng/mL were included. In bivariate analysis, a positive finding on MI (local or metastatic) was associated with decision to use ADT with an odds ratio of 3.67 (95% CI, 1.25 to 10.71; p = 0.02). No factor included in the nomogram was associated with decision to use ADT. Also, MI improved selection of patients to receive ADT based on predicted BCR after sRT : the predicted nomogram 5-year biochemical-free survivals were 52.5% and 43.3%, (mean difference, 9.2%; 95% CI 0.8 to 17.6; p = 0.03) for sRT alone and ADT±sRT subgroups, while there was no statistically significant difference between subgroups before MI. / Conclusions: PSMA and/or Choline PET/CT before sRT can potentially improve patient ADT management by directing clinicians towards more appropriate intensification. date: 2023-06-08 date_type: published publisher: BMC official_url: https://doi.org/10.1186/s40644-023-00570-x oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 2029349 doi: 10.1186/s40644-023-00570-x medium: Electronic pii: 10.1186/s40644-023-00570-x lyricists_name: Punwani, Shonit lyricists_id: SPUNW14 actors_name: Flynn, Bernadette actors_id: BFFLY94 actors_role: owner funding_acknowledgements: Movember Foundation [Movember Foundation] full_text_status: public publication: Cancer Imaging volume: 23 number: 1 article_number: 57 pages: 7 event_location: England issn: 1740-5025 citation: Tremblay, Samuel; Alhogbani, Mofarej; Weickhardt, Andrew; Davis, Ian D; Scott, Andrew M; Hicks, Rodney J; Metser, Ur; ... Pouliot, Frederic; + view all <#> Tremblay, Samuel; Alhogbani, Mofarej; Weickhardt, Andrew; Davis, Ian D; Scott, Andrew M; Hicks, Rodney J; Metser, Ur; Chua, Sue; Davda, Reena; Punwani, Shonit; Payne, Heather; Tunariu, Nina; Ho, Bao; Young, Sympascho; Singbo, Mahukpe Narcisse Ulrich; Bauman, Glenn; Emmett, Louise; Pouliot, Frederic; - view fewer <#> (2023) Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial. Cancer Imaging , 23 (1) , Article 57. 10.1186/s40644-023-00570-x <https://doi.org/10.1186/s40644-023-00570-x>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10183313/1/s40644-023-00570-x.pdf